Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Receives Average Recommendation of Hold from Brokerages

Shares of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE – Get Rating) have earned a consensus rating of “Hold” from the six analysts that are currently covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a hold rating. The average 1-year target price among analysts that have updated their coverage on the stock in […]

Related Keywords

Aeglea Biotherapeutics ,Aeglea Biotherapeutics Inc ,Wells Fargo Company ,Nantahala Capital Management ,Acadian Asset Management ,Nasdaq ,Charles Schwab Investment Management Inc ,Get Rating ,Wells Fargo ,Asset Management ,Capital Management ,Schwab Investment Management ,Street Corp ,Rock Springs Capital Management ,Springs Capital Management ,